Cargando…

Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study

The comparative efficacy and safety between lenvatinib and hepatic artery infusion chemotherapy (HAIC) in patients with unresectable hepatocellular carcinoma (HCC) is still unclear. This multicenter historical cohort study enrolled 244 patients who were treated with HAIC (n = 173) or lenvatinib (n =...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jaejun, Han, Ji-Won, Sung, Pil-Soo, Lee, Soon-Kyu, Yang, Hyun, Nam, Hee-Chul, Yoo, Sun-Hong, Lee, Hae-Lim, Kim, Hee-Yeon, Lee, Sung-Won, Kwon, Jung-Hyun, Jang, Jeong-Won, Kim, Chang-Wook, Nam, Soon-Woo, Oh, Jung-Suk, Chun, Ho-Jong, Bae, Si-Hyun, Choi, Jong-Young, Yoon, Seung-Kew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464794/
https://www.ncbi.nlm.nih.gov/pubmed/34575160
http://dx.doi.org/10.3390/jcm10184045
_version_ 1784572705400422400
author Lee, Jaejun
Han, Ji-Won
Sung, Pil-Soo
Lee, Soon-Kyu
Yang, Hyun
Nam, Hee-Chul
Yoo, Sun-Hong
Lee, Hae-Lim
Kim, Hee-Yeon
Lee, Sung-Won
Kwon, Jung-Hyun
Jang, Jeong-Won
Kim, Chang-Wook
Nam, Soon-Woo
Oh, Jung-Suk
Chun, Ho-Jong
Bae, Si-Hyun
Choi, Jong-Young
Yoon, Seung-Kew
author_facet Lee, Jaejun
Han, Ji-Won
Sung, Pil-Soo
Lee, Soon-Kyu
Yang, Hyun
Nam, Hee-Chul
Yoo, Sun-Hong
Lee, Hae-Lim
Kim, Hee-Yeon
Lee, Sung-Won
Kwon, Jung-Hyun
Jang, Jeong-Won
Kim, Chang-Wook
Nam, Soon-Woo
Oh, Jung-Suk
Chun, Ho-Jong
Bae, Si-Hyun
Choi, Jong-Young
Yoon, Seung-Kew
author_sort Lee, Jaejun
collection PubMed
description The comparative efficacy and safety between lenvatinib and hepatic artery infusion chemotherapy (HAIC) in patients with unresectable hepatocellular carcinoma (HCC) is still unclear. This multicenter historical cohort study enrolled 244 patients who were treated with HAIC (n = 173) or lenvatinib (n = 71) between 2012 and 2020. Propensity score matching (PSM) was performed, and 52 patients were selected per group. Clinical outcomes and safety were compared. Objective response rate (ORR) was not different between the two groups (26.0% vs. 23.1%, p = 0.736). Before PSM, the HAIC group had a higher proportion of Child-Pugh B and portal vein tumor, whereas the lenvatinib group had more patients with extrahepatic metastases, which was adjusted after PSM. There were no differences in progression-free survival (PFS) and overall survival (OS) after PSM (HAIC vs. lenvatinib, median PFS, 3.6 vs. 4.0 months, p = 0.706; median OS 10.8 vs. 7.9 months, p = 0.106). Multivariate Cox-regression showed that alpha-fetoprotein ≤1000 ng/mL was only an associated factor for OS after PSM in all patients (hazard ratio = 0.421, p = 0.011). Subgroup analysis for patients with a high tumor burden beyond the REFLECT eligibility criteria revealed that the HAIC group (n = 29) had a significantly longer OS than did the lenvatinib group (n = 30) (10.0 vs. 5.4 months, p = 0.004). More patients in the HAIC group achieved better liver function than those in the lenvatinib group at the time of best responses. There was no difference in the incidence of grade 3 and 4 adverse events between the two groups. Therefore, lenvatinib is comparable to HAIC in terms of ORR and OS in unresectable HCC meeting REFLECT eligibility criteria.
format Online
Article
Text
id pubmed-8464794
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84647942021-09-27 Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study Lee, Jaejun Han, Ji-Won Sung, Pil-Soo Lee, Soon-Kyu Yang, Hyun Nam, Hee-Chul Yoo, Sun-Hong Lee, Hae-Lim Kim, Hee-Yeon Lee, Sung-Won Kwon, Jung-Hyun Jang, Jeong-Won Kim, Chang-Wook Nam, Soon-Woo Oh, Jung-Suk Chun, Ho-Jong Bae, Si-Hyun Choi, Jong-Young Yoon, Seung-Kew J Clin Med Article The comparative efficacy and safety between lenvatinib and hepatic artery infusion chemotherapy (HAIC) in patients with unresectable hepatocellular carcinoma (HCC) is still unclear. This multicenter historical cohort study enrolled 244 patients who were treated with HAIC (n = 173) or lenvatinib (n = 71) between 2012 and 2020. Propensity score matching (PSM) was performed, and 52 patients were selected per group. Clinical outcomes and safety were compared. Objective response rate (ORR) was not different between the two groups (26.0% vs. 23.1%, p = 0.736). Before PSM, the HAIC group had a higher proportion of Child-Pugh B and portal vein tumor, whereas the lenvatinib group had more patients with extrahepatic metastases, which was adjusted after PSM. There were no differences in progression-free survival (PFS) and overall survival (OS) after PSM (HAIC vs. lenvatinib, median PFS, 3.6 vs. 4.0 months, p = 0.706; median OS 10.8 vs. 7.9 months, p = 0.106). Multivariate Cox-regression showed that alpha-fetoprotein ≤1000 ng/mL was only an associated factor for OS after PSM in all patients (hazard ratio = 0.421, p = 0.011). Subgroup analysis for patients with a high tumor burden beyond the REFLECT eligibility criteria revealed that the HAIC group (n = 29) had a significantly longer OS than did the lenvatinib group (n = 30) (10.0 vs. 5.4 months, p = 0.004). More patients in the HAIC group achieved better liver function than those in the lenvatinib group at the time of best responses. There was no difference in the incidence of grade 3 and 4 adverse events between the two groups. Therefore, lenvatinib is comparable to HAIC in terms of ORR and OS in unresectable HCC meeting REFLECT eligibility criteria. MDPI 2021-09-07 /pmc/articles/PMC8464794/ /pubmed/34575160 http://dx.doi.org/10.3390/jcm10184045 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lee, Jaejun
Han, Ji-Won
Sung, Pil-Soo
Lee, Soon-Kyu
Yang, Hyun
Nam, Hee-Chul
Yoo, Sun-Hong
Lee, Hae-Lim
Kim, Hee-Yeon
Lee, Sung-Won
Kwon, Jung-Hyun
Jang, Jeong-Won
Kim, Chang-Wook
Nam, Soon-Woo
Oh, Jung-Suk
Chun, Ho-Jong
Bae, Si-Hyun
Choi, Jong-Young
Yoon, Seung-Kew
Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study
title Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study
title_full Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study
title_fullStr Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study
title_full_unstemmed Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study
title_short Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study
title_sort comparative analysis of lenvatinib and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma: a multi-center, propensity score study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464794/
https://www.ncbi.nlm.nih.gov/pubmed/34575160
http://dx.doi.org/10.3390/jcm10184045
work_keys_str_mv AT leejaejun comparativeanalysisoflenvatinibandhepaticarterialinfusionchemotherapyinunresectablehepatocellularcarcinomaamulticenterpropensityscorestudy
AT hanjiwon comparativeanalysisoflenvatinibandhepaticarterialinfusionchemotherapyinunresectablehepatocellularcarcinomaamulticenterpropensityscorestudy
AT sungpilsoo comparativeanalysisoflenvatinibandhepaticarterialinfusionchemotherapyinunresectablehepatocellularcarcinomaamulticenterpropensityscorestudy
AT leesoonkyu comparativeanalysisoflenvatinibandhepaticarterialinfusionchemotherapyinunresectablehepatocellularcarcinomaamulticenterpropensityscorestudy
AT yanghyun comparativeanalysisoflenvatinibandhepaticarterialinfusionchemotherapyinunresectablehepatocellularcarcinomaamulticenterpropensityscorestudy
AT namheechul comparativeanalysisoflenvatinibandhepaticarterialinfusionchemotherapyinunresectablehepatocellularcarcinomaamulticenterpropensityscorestudy
AT yoosunhong comparativeanalysisoflenvatinibandhepaticarterialinfusionchemotherapyinunresectablehepatocellularcarcinomaamulticenterpropensityscorestudy
AT leehaelim comparativeanalysisoflenvatinibandhepaticarterialinfusionchemotherapyinunresectablehepatocellularcarcinomaamulticenterpropensityscorestudy
AT kimheeyeon comparativeanalysisoflenvatinibandhepaticarterialinfusionchemotherapyinunresectablehepatocellularcarcinomaamulticenterpropensityscorestudy
AT leesungwon comparativeanalysisoflenvatinibandhepaticarterialinfusionchemotherapyinunresectablehepatocellularcarcinomaamulticenterpropensityscorestudy
AT kwonjunghyun comparativeanalysisoflenvatinibandhepaticarterialinfusionchemotherapyinunresectablehepatocellularcarcinomaamulticenterpropensityscorestudy
AT jangjeongwon comparativeanalysisoflenvatinibandhepaticarterialinfusionchemotherapyinunresectablehepatocellularcarcinomaamulticenterpropensityscorestudy
AT kimchangwook comparativeanalysisoflenvatinibandhepaticarterialinfusionchemotherapyinunresectablehepatocellularcarcinomaamulticenterpropensityscorestudy
AT namsoonwoo comparativeanalysisoflenvatinibandhepaticarterialinfusionchemotherapyinunresectablehepatocellularcarcinomaamulticenterpropensityscorestudy
AT ohjungsuk comparativeanalysisoflenvatinibandhepaticarterialinfusionchemotherapyinunresectablehepatocellularcarcinomaamulticenterpropensityscorestudy
AT chunhojong comparativeanalysisoflenvatinibandhepaticarterialinfusionchemotherapyinunresectablehepatocellularcarcinomaamulticenterpropensityscorestudy
AT baesihyun comparativeanalysisoflenvatinibandhepaticarterialinfusionchemotherapyinunresectablehepatocellularcarcinomaamulticenterpropensityscorestudy
AT choijongyoung comparativeanalysisoflenvatinibandhepaticarterialinfusionchemotherapyinunresectablehepatocellularcarcinomaamulticenterpropensityscorestudy
AT yoonseungkew comparativeanalysisoflenvatinibandhepaticarterialinfusionchemotherapyinunresectablehepatocellularcarcinomaamulticenterpropensityscorestudy